<i>In silico</i> Design, Synthesis and Biological Evaluation of Novel Thieno[3,2‐<i>d</i>]pyrimidine Derivatives for Cancer Therapy – A Preliminary Study on the Inhibitory Potential towards ATR Kinase Domain and PIKK Family
作者:Samvel N. Sirakanyan、Haritha Dilip、Athina Geronikaki、Domenico Spinelli、Sivapriya Kirubakaran、Anthi Petrou、Elmira K. Hakobyan、Victor G. Kartsev、Ervand G. Paronikyan、Hasmik A. Yegoryan、Lilit V. Yermalovyan、Anush A. Hovakimyan
DOI:10.1002/cbdv.202302071
日期:2024.3
compounds with biological interest, herein we report the synthesis and anticancer activity of new N- and S-substituted derivatives of tetracyclic pyrido[3′,2′ : 4,5]thieno[3,2-d]pyrimidines. In this regard, starting from the thieno[2,3-b]pyridine-2-carboxylates, the corresponding 8(9)-aminopyrido[3′,2′ : 4,5]thieno[3,2-d]pyrimidin-7(8)-ones, as well as chloro derivatives were obtained. Based on the
继续我们在具有
生物学意义的新型
杂环化合物领域的研究,本文报道了新型四环
吡啶并[3',2' : 4,5]
噻吩并[3,2]的N-和S-取代衍
生物的合成和抗癌活性-d ]
嘧啶。在这方面,从
噻吩并[2,3- b ]
吡啶-2-
羧酸盐开始,相应的8(9)-
氨基吡啶并[3',2':4,5]
噻吩并[3,2- d ]
嘧啶-获得了7(8)-酮以及
氯代衍
生物。在此基础上,随后合成了
吡啶并[3',2':4,5]
噻吩并[3,2- d ]
嘧啶的
氨基、
肼基和S-烷基衍
生物。目前的研究重点是通过计算预测确定
噻吩并[3,2- d ]
嘧啶衍
生物主要抑制 ATR 激酶的潜力,然后进行合成和癌细胞活力研究,并旨在开发作为
PIKK
抑制剂的核心癌症治疗。